18F-labelling of a cyclic pentapeptide inhibitor of the chemokine receptor CXCR4

被引：13

作者：

Aberg, Ola ^{[1
]}

Pisaneschi, Federica ^{[1
]}

Smith, Graham ^{[1
]}

Quang-De Nguyen ^{[1
]}

Stevens, Elizabeth ^{[1
]}

Aboagye, Eric O. ^{[1
]}

机构：

[1] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Fac Med, Comprehens Canc Imaging Ctr,Dept Surg & Canc, London W12 0NN, England

来源：

JOURNAL OF FLUORINE CHEMISTRY | 2012年 / 135卷

基金：

英国医学研究理事会; 英国工程与自然科学研究理事会;

关键词：

CXCR4; Cyclic pentapeptide; PET imaging; F-18]fluorobenzaldehyde; Radiolabelling; POSITRON-EMISSION-TOMOGRAPHY; BREAST-CANCER METASTASIS; SMALL-MOLECULE; ANTAGONIST; F-18; PEPTIDES; PET; IDENTIFICATION; EXPRESSION; FLUORIDES;

D O I：

10.1016/j.jfluchem.2011.11.003

中图分类号：

O61 [无机化学];

学科分类号：

070301 ; 081704 ;

摘要：

The chemokine receptor CXCR4 is overexpressed in a variety of cancers including breast, prostate and lung cancer. Expression is also associated with invasion and metastasis. The possibility to image and quantify CXCR4 expression in vivo would be a valuable tool in the clinic to aid treatment regimens and to potentially understand the underlying biology of metastasis. Herein we describe the synthesis and the radiolabelling of an F-18-labelled cyclic pentapeptide, [F-18]CCIC-0007 designed to bind to the extracellular domains of CXCR4. Radiolabelling was performed via conjugation of [F-18]fluorobenzaldehyde with an aminooxy functionalised cyclopentapeptide. Typically, starting with 1.10 GBq (30 mCi) of aqueous [F-18]fluoride, 105 MBq (2.85 mCi) of the formulated tracer was obtained within 2.5 h (23 +/- 8% dc rcy, 8% EOS yield). Tissue pharmacokinetic studies in mice demonstrated rapid blood clearance, together with biliary and renal elimination. (C) 2011 Elsevier B.V. All rights reserved.

引用

页码：200 / 206

页数：7

共 37 条

[11] PET imaging of CXCR4 using copper-64 labeled peptide antagonist
Jacobson, Orit
Weiss, Ido D.
Szajek, Lawrence P.
Niu, Gang
Ma, Ying
Kiesewetter, Dale O.
Farber, Joshua M.
Chen, Xiaoyuan
[J]. THERANOSTICS, 2011, 1 : 251 - 262
[12] Jacobson O, 2010, J NUCL MED, V51, P1796, DOI 10.2967/jnumed.110.079418
[13] Binding Optimization through Coordination Chemistry: CXCR4 Chemokine Receptor Antagonists from Ultrarigid Metal Complexes
Khan, Abid
Nicholson, Gary
Greenman, John
Madden, Leih
McRobbie, Graeme
Pannecouque, Christophe
De Clercq, Erik
Ullom, Robert
Maples, Danny L.
Maples, Randall D.
Silversides, Jon D.
Hubin, Timothy J.
Archibald, Stephen J.
[J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2009, 131 (10) : 3416 - +
[14] Koglin N., 2006, J NUCL MED, V47
[15] The Challenge of Labeling Macromolecules with Fluorine-18: Three Decades of Research
Kuhnast, Bertrand
Dolle, Frederic
[J]. CURRENT RADIOPHARMACEUTICALS, 2010, 3 (03) : 174 - 201
[16] Laruelle Marc, 2003, Mol Imaging Biol, V5, P363, DOI 10.1016/j.mibio.2003.09.009
[17] Fluorine-18 and medical imaging: Radiopharmaceuticals for positron emission tomography
Le Bars, Didier
[J]. JOURNAL OF FLUORINE CHEMISTRY, 2006, 127 (11) : 1488 - 1493
[18] Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4
Liang, ZX
Wu, T
Lou, H
Yu, XW
Taichman, RS
Lau, SK
Nie, SM
Umbreit, J
Shim, H
[J]. CANCER RESEARCH, 2004, 64 (12) : 4302 - 4308
[19] Liang ZX, 2005, CANCER RES, V65, P967
[20] CXCL12-CXCR4 Axis in Angiogenesis, Metastasis and Stem Cell Mobilization
Liekens, S.
Schols, D.
Hatse, S.
[J]. CURRENT PHARMACEUTICAL DESIGN, 2010, 16 (35) : 3903 - 3920

← 1 2 3 4 →